IE
STRO icon

Israel Englander’s Sutro Biopharma STRO Stock Holding History

Israel Englander’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,460
Closed -$545K – 7480
2022
Q2 		$545K Buy
+10,460
New +$584K ﹤0.01% 4880
2021
Q2 		– Sell
-2,500
Closed -$569K – 7078
2021
Q1 		$569K Buy
+2,500
New +$593K ﹤0.01% 4723

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Israel Englander's STRO Position: Q2 2026 in Review

Israel Englander increased its Sutro Biopharma (STRO) stake by 74% in Q2 2026, buying an estimated $4.85M and bringing the position to 365,972 shares worth $12.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2093.

Israel Englander first reported a position in STRO in Q3 2018 and has held it in 31 quarters since. The position peaked at $26.8M in Q1 2024. 99 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Israel Englander held 365,972 shares of Sutro Biopharma worth $12.2M as of Q2 2026.
  • Israel Englander bought 155,594 Sutro Biopharma shares in Q2 2026, an estimated $4.85M.
  • Sutro Biopharma made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2093 holding.
  • Israel Englander first reported a position in Sutro Biopharma in Q3 2018 and has held it in 31 quarters since.
  • Israel Englander's Sutro Biopharma position peaked at $26.8M in Q1 2024.
  • 99 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.